

# Giuseppe Lopalco

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9347951/giuseppe-lopalco-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158  
papers

2,456  
citations

28  
h-index

40  
g-index

189  
ext. papers

3,189  
ext. citations

3.7  
avg, IF

5.07  
L-index

#	Paper	IF	Citations
158	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 191-197	3.9	74
157	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1281-6	3.9	72
156	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 1-9	13.6	70
155	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 369	5.6	68
154	Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 194864	4.3	64
153	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , <b>2015</b> , 62, 40-6	11.2	60
152	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 183-189	3.9	59
151	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 380	5.6	57
150	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 956-964	3.9	53
149	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2233-2240	3.9	52
148	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1197-207	3.9	49
147	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 463-468	3.9	48
146	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 451-455	3.9	45
145	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 447-50	13.6	44
144	Interleukin 1 $\alpha$ comprehensive review on the role of IL-1 $\alpha$ in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102763	13.6	44
143	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 90-7	13.6	42
142	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 475-489	3.7	42

141	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 200	8.4	42
140	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	41
139	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1141-3	3.9	40
138	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	37
137	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 17-28	3.9	36
136	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 407-415	3.9	34
135	New therapeutic solutions for Behçet's syndrome. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 827-409	3.9	31
134	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , <b>2018</b> , 102, 637-641	5.5	30
133	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1528	1.8	30
132	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 570418	4.3	29
131	Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e13013	4.6	28
130	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behçet's Disease. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1858	1.8	28
129	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2805-2809	3.9	28
128	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 1031-1035	3.3	27
127	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , <b>2020</b> , 28, 298-304	2.8	26
126	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 34-39	2.8	25
125	IL-6 blockade in the management of non-infectious uveitis. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1459-1469	3.9	24
124	COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. <i>Rheumatology International</i> , <b>2020</b> , 40, 827-828	3.6	24

123	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 501-5	3.9	24
122	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2063-2069	3.9	23
121	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. <i>Rheumatology International</i> , <b>2019</b> , 39, 971-990	3.6	23
120	Untangling the web of systemic autoinflammatory diseases. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 948154	1.5	22
119	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 63-70	3.9	22
118	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 531-8	2.2	22
117	Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , <b>2016</b> , 18, 171-6	0.9	22
116	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1050-1051	2.3	21
115	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 61	4.2	21
114	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , <b>2018</b> , 2018, 2453265	4.3	21
113	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 103-108	2.3	19
112	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2631-2638	3.9	19
111	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 77-81	2.2	19
110	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 680-683	2.2	19
109	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 296	5.6	17
108	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 807-9	3.9	17
107	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 451675	4.3	17
106	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet's disease. <i>Immunology Letters</i> , <b>2018</b> , 201, 38-44	4.1	17

105	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , <b>2015</b> , 17, 93-7	0.9	17
104	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behçet's Disease with Different Organ Involvement: A Case Series. <i>Israel Medical Association Journal</i> , <b>2016</b> , 18, 238-42	0.9	17
103	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1098-1104	2.4	16
102	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 1623847	4.3	16
101	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 1599-1606	3.9	15
100	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2363-7	3.9	15
99	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1736-1737	2.4	15
98	Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials. <i>Pain Research and Treatment</i> , <b>2017</b> , 2017, 9747148	1.9	14
97	Update on the Medical Management of Gastrointestinal Behçet's Disease. <i>Mediators of Inflammation</i> , <b>2017</b> , 2017, 1460491	4.3	14
96	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 68-73	2.2	14
95	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 918	5.6	13
94	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1503-11	3.9	13
93	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 911-7	4.1	13
92	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1165-7	3.9	13
91	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8562485	4.3	13
90	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1171-80	3.9	12
89	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1715-1720	3.9	12
88	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 424-9	2.2	11

87	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 187-195	2.2	11
86	Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 1086-1088	1.6	10
85	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8294560	4.3	10
84	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 781-91	3.7	10
83	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 1309-1317	3.9	9
82	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 719-722	3.7	9
81	A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1457-1465	3.7	9
80	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 265-274	6.9	9
79	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 762-767	2.2	9
78	Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review. <i>Rheumatology International</i> , <b>2018</b> , 38, 25-35	3.6	8
77	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 19-23	3.9	8
76	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8054961	4.3	8
75	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 6983272	4.3	8
74	Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol. <i>Journal of Dermatology</i> , <b>2017</b> , 44, 981-982	1.6	7
73	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , <b>2020</b> , 28, 711-718	5.1	7
72	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , <b>2020</b> , 6,	5.9	7
71	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	7
70	Management of Small Vessel Vasculitides. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 36	4.9	7



69	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1468	5.6	7
68	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> ,	1.1	7
67	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 353	2.2	7
66	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 93-97	2.2	7
65	Efficacy of anti-tumour necrosis factor- $\gamma$ monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 301-305	2.2	7
64	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1526	5.6	6
63	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 42	4.9	6
62	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1031-1039	3.7	6
61	Different switching rate of anti-TNF- $\gamma$ drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 458-9	2.9	6
60	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S171-2	2.2	6
59	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 415-419	0.9	6
58	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 438-441	0.9	6
57	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 187-195	2.2	6
56	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 473-5	2.3	5
55	Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2495-6	4.1	5
54	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105062	2.9	5
53	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 74, 295	9.5	5
52	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 130-131	2.2	5

51	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 227-227	2.2	5
50	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 201, 200-204	6.2	4
49	Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 42, 102152	4	3
48	Auditory involvement in Behçet's disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 445-449	3.9	3
47	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	3
46	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , <b>2014</b> , 65, 298-301	1.1	3
45	Safety of systemic treatments for Behçet's syndrome. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 1269-1301	4.1	3
44	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 668173	4.9	3
43	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e104	2.4	3
42	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2019</b> ,	3.9	3
41	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 517-521	0.9	3
40	Effectiveness of TNF- $\beta$ blockade in the treatment of refractory non-infectious scleritis: a multicentre study. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 1138-1144	2.2	3
39	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, e70	2.4	2
38	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 908-12	2.3	2
37	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 899	5	2
36	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e122	1.1	2
35	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.. <i>RMD Open</i> , <b>2022</b> , 8,	5.9	2
34	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , <b>2021</b> , 89, 105299	2.9	2



33	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, e208-e209	1.1	2
32	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. <i>Rheumatology</i> , <b>2019</b> , 58, 440	3.9	2
31	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13363	4.6	2
30	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e73-e74	1.1	2
29	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 170-171	2.2	2
28	SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 747.1-747	2.4	1
27	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. <i>Reumatismo</i> , <b>2015</b> , 67, 17-20	1.1	1
26	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 887	5	1
25	OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 94-95	2.4	1
24	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 278	5.7	1
23	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2163-2171	3.7	1
22	OP0093 RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER'S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 51-52	2.4	1
21	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , <b>2021</b> , 60, 5705-5712	3.9	1
20	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 227	2.2	1
19	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 860877	8.4	1
18	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , <b>2020</b> , 35, 163-169	0.9	0
17	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 3659-3665	3.9	0
16	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211037178	3.8	0

15	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 1	3.7	○
14	Development and Implementation of the AIDA International Registry for Patients With Still's Disease.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 878797	4.9	○
13	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 769870	4.9	○
12	SAT0384 Long-Term Safety of Anti-Tnf Agents in Patients with Spondyloarthritis and Potential Occult HBV: An Observational Multicenter Study on 131 Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 807.1-807	2.4	
11	AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 912.2-912	2.4	
10	AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1046.3-1047	2.4	
9	AB0844 SERUM sCD40L LEVEL CAN PREDICT SHORT-TERM CLINICAL OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS ON TREATMENT WITH APREMILAST.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1728-1729	2.4	
8	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, e102	1.1	
7	AB0380 MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERING. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1217-1217	2.4	
6	POS0631 COMPARATIVE EFFICACY OF COMBINATION THERAPY WITH BIOLOGIC OR TARGET SYNTHETIC DRUGS FOR RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 553.2-554	2.4	
5	Response to: 'Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro ' by Agca. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e106	2.4	
4	Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF). <i>Joint Bone Spine</i> , <b>2021</b> , 89, 105259	2.9	
3	Efficacy of monoclonal anti-tumour necrosis factor- $\alpha$ antibodies in uveitic macular oedema. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 621-625	2.2	
2	Reply to Praprotnik and Tomsic and erratum corrigé. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 1034	2.2	
1	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 1147-1148	2.2	